Core Insights - Hims & Hers Health Inc. is under investigation by Berger Montague for potential breaches of fiduciary duties following the termination of its partnership with Novo Nordisk due to deceptive marketing practices [1][6] - Insider trading activity by Chief Commercial Officer Chi Michael, who sold 13,749 shares at $50.50 each, raises questions about confidence in the company's future amid ongoing legal scrutiny [2][6] - Hims & Hers has a high price-to-earnings (P/E) ratio of 67.01, indicating strong investor expectations for growth despite current challenges [3][6] Financial Metrics - The company has a price-to-sales ratio of 6.25 and an enterprise value to sales ratio of 6.21, reflecting the market's valuation of its sales [4] - Hims & Hers has an enterprise value to operating cash flow ratio of 47.79, indicating its valuation in relation to cash flow from operations [4] - The debt-to-equity ratio stands at 1.86, suggesting a moderate level of financial leverage, while a current ratio of 4.98 indicates strong short-term liability coverage [5]

Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc., following a class action lawsuit filed on behalf of investors who acquired RxSight securities between May 7, 2024, and July 8, 2025 [1][2]. Company Overview - RxSight, headquartered in Aliso Viejo, CA, is a medical technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery, utilizing the Company's Light Delivery Device (LDD) [2]. Legal Allegations - The lawsuit alleges that RxSight's management failed to disclose significant issues, including: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3]. 2. Overstated demand for RxSight's products [3]. 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz attributed the stall in LDD sales to adoption challenges over recent quarters [4]. - Following this announcement, RxSight shares fell by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4].

Core Viewpoint - Berger Montague PC is investigating potential securities fraud claims against CTO Realty Growth, Inc. following a class action lawsuit related to allegations of financial manipulation during a specified class period [1][3]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who acquired CTO securities between February 18, 2021, and June 24, 2025 [1][2]. - The lawsuit alleges that a report by Wolfpack Research accused CTO of covering a $38 million dividend gap through significant share dilution and excluding necessary recurring capital expenditures from its Adjusted Funds From Operations [3]. Group 2: Stock Performance - Following the allegations made in the report, CTO's stock price fell nearly 6%, closing at $17.10 per share on June 25, 2025 [4]. Group 3: Company Background - CTO Realty Growth, Inc. is a real estate investment trust (REIT) headquartered in Winter Park, Florida [2].

PHILADELPHIA , Sept. 15, 2025 /PRNewswire/ --Â Berger Montague, a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) about an investigation into Hims & Hers' Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Novo Nordisk A/S's termination of its partnership with Hims & Hers. ...

Group 1 - RxSight, Inc. is under investigation for potential securities fraud claims following significant declines in sales and revenue [1][2] - The company reported a 37% drop in share price, closing at $7.95 per share after disclosing adoption challenges affecting LDD sales and LAL utilization [2] - Investors who acquired RxSight stock between November 7, 2024, and July 8, 2025, may seek lead plaintiff status in the ongoing litigation [3] Group 2 - RxSight specializes in medical technology, specifically developing light adjustable intraocular lenses (LAL) for cataract surgery [1] - The company's Light Delivery Device (LDD) is a key component of its RxSight system [1]

Core Viewpoint - Berger Montague PC is investigating potential securities fraud claims against Novo Nordisk A/S following a securities class action lawsuit filed on behalf of investors who acquired Novo securities during the Class Period from May 7, 2025, to July 28, 2025 [1][3] Group 1 - The lawsuit alleges that Novo Nordisk made false and misleading statements regarding the impact of compounded GLP-1 drugs, specifically underestimating the effect of the FDA's personalization exception [3] - The company allegedly overstated the likelihood that patients would switch to its branded drugs, such as Ozempic® and Wegovy®, leading to significant investor losses [3] - Investors who purchased Novo securities during the Class Period have until September 30, 2025, to seek appointment as lead plaintiff representative of the class [2]

Core Viewpoint - Berger Montague PC is investigating claims against Fiserv, Inc. following a class action lawsuit alleging that the company overstated its growth by not disclosing issues with its Clover payment platform [1][3]. Group 1: Lawsuit Details - The class action lawsuit claims that Fiserv and certain executives failed to disclose that Clover's revenue growth was artificially inflated due to the forced transition of merchants from the legacy Payeezy platform [3]. - Investors became aware of Fiserv's true financial situation after the company lowered its 2025 organic growth projections on July 23, 2025, leading to a significant decline in share price [4]. Group 2: Investor Information - Investors who purchased Fiserv securities between July 24, 2024, and July 22, 2025, have until September 22, 2025, to seek appointment as lead plaintiff representatives [2][5].

Core Viewpoint - Berger Montague PC is investigating potential securities fraud claims against CTO Realty Growth, Inc. following a class action lawsuit related to alleged financial manipulation during the Class Period from February 18, 2021, to June 24, 2025 [1][3]. Group 1: Company Overview - CTO Realty Growth, Inc. is a real estate investment trust (REIT) headquartered in Winter Park, Florida [2]. Group 2: Legal Allegations - The lawsuit alleges that on June 25, 2025, Wolfpack Research published a report accusing CTO of financial manipulation, claiming the company covered a $38 million dividend gap by significantly diluting its shares and excluding necessary recurring capital expenditures from its Adjusted Funds From Operations [3]. - The report also alleged that CTO used a "sham loan" to conceal a major tenant failure at Ashford Lane, a key property [3]. Group 3: Market Reaction - Following the allegations, CTO's stock price fell nearly 6%, closing at $17.10 per share on June 25, 2025 [4].

Core Viewpoint - Berger Montague is investigating potential securities fraud claims against Petco Health and Wellness Company, following a federal securities class action lawsuit related to misleading statements about its pandemic-driven growth and product strategy [1][2]. Summary by Relevant Sections Allegations of Misleading Statements - The complaint alleges that Petco made false and misleading statements regarding the sustainability of its pandemic-driven growth and premium product strategy, which led to a significant decline in its stock price, including a drop of over 20% on August 24, 2023 [2]. Impact on Stock Price and Investor Confidence - The lawsuit indicates that the alleged misstatements contributed to substantial losses for Petco, particularly during the Class Period from January 14, 2021, to June 5, 2025, with continued downward revisions to earnings guidance and multiple leadership changes affecting investor confidence [2][3]. Changes in Product Strategy - Petco's efforts to adjust its product mix by introducing lower-cost pet food options contradicted prior public statements, highlighting the severity of the Company's challenges and further impacting investor sentiment [3].

Core Viewpoint - Berger Montague is investigating potential securities law violations involving Petco Health and Wellness Company, with a class action lawsuit filed for investors who acquired Petco securities between January 14, 2021, and June 5, 2025 [1][2] Group 1: Legal Action and Allegations - A class action lawsuit has been initiated on behalf of investors who purchased Petco securities during the specified Class Period [1][2] - The complaint alleges that Petco made materially false and misleading statements regarding its pandemic-related advantages and the sustainability of its premium pet food business model [3] - It is claimed that the Company overstated its ability to achieve profitable growth while downplaying operational challenges, leading to significant stock price declines [3] Group 2: Stock Performance Impact - Petco's stock price experienced a drop of over 20% on August 24, 2023, following a downward revision of its financial guidance [3] - Further declines in stock price occurred after subsequent disclosures and changes in leadership [3]